Progression-free survival outcomes of PARP inhibitors in ovarian cancer: an exploratory analysis of treatment heterogeneity based on organ vulnerability - Top-Institutions - MDSpire

Progression-free survival outcomes of PARP inhibitors in ovarian cancer: an exploratory analysis of treatment heterogeneity based on organ vulnerability

By
Xing Zhou
Xi’an Xiong
Zhen Yang
Zhongping Cao
Qianxi Ni
July 3, 2026
0 min

Frontiers In Oncology

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

#1

The University of Texas MD Anderson Cancer Center

Houston, Texas
Key Differentiators
- Oncology
#2

Memorial Sloan Kettering Cancer Center

New York, New York
Key Differentiators
- Oncology
#3

Clinica Universidad de Navarra

Pamplona, Navarra
Key Differentiators
- Oncology
#4

Español de Investigación en Cáncer de Ovario

Madrid, Madrid
Key Differentiators
- Oncology
#5

OhioHealth Riverside Methodist Hospital

Columbus, Ohio
Key Differentiators
- Oncology